Paper26164151
RAD1901: a novel, orally bioavailable selective estrogen receptor degrader that demonstrates antitumor activity in breast cancer xenograft models.
Garner F and 4 others. Anticancer Drugs, 2015. Cited by 132 papers, by iCite.
Cite this record
ConductScience Library. RAD1901: a novel, orally bioavailable selective estrogen receptor degrader that demonstrates antitumor activity in breast cancer xenograft models. Papers, record 26164151. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/26164151
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- RAD1901: a novel, orally bioavailable selective estrogen receptor degrader that demonstrates antitumor activity in breast cancer xenograft models.
- PubMed
Topics20
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Antineoplastic Agents | Major topic |
| Brain Neoplasms | Major topic |
| Breast Neoplasms | Major topic |
| Estrogen Receptor alpha | Major topic |
| Phenylurea Compounds | Major topic |
| ortho-Aminobenzoates | Major topic |
| Administration, Oral | |
| Animals | |
| Binding, Competitive | |
| Bone Density | |
| Cell Proliferation | |
| Female | |
| Heterografts | |
| MCF-7 Cells | |
| Mice, Nude | |
| Neoplasm Transplantation | |
| Osteoporosis | |
| Ovariectomy | |
| Rats, Sprague-Dawley | |
| Uterus |
Source PubMed
References20
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 16092128 | Steroid hormone receptor signaling in tumorigenesis. | J Cell Biochem | 2005 | https://conductscience.org/library/papers/16092128 | PubMed |
| 2 | 1773131 | The ovariectomized rat model of postmenopausal bone loss. | Bone Miner | 1991 | https://conductscience.org/library/papers/1773131 | PubMed |
| 3 | 16515478 | Estrogen receptors as therapeutic targets in breast cancer. | Curr Top Med Chem | 2006 | https://conductscience.org/library/papers/16515478 | PubMed |
| 4 | 17186017 | Chemoprevention of breast cancer with selective oestrogen-receptor modulators. | Nat Rev Cancer | 2007 | https://conductscience.org/library/papers/17186017 | PubMed |
| 5 | 17259555 | Estrogen-related receptor alpha as a therapeutic target in cancer. | Endocr Relat Cancer | 2006 | https://conductscience.org/library/papers/17259555 | PubMed |
| 6 | 17440819 | SERMs for the treatment and prevention of breast cancer. | Rev Endocr Metab Disord | 2007 | https://conductscience.org/library/papers/17440819 | PubMed |
| 7 | 17993238 | Estrogen receptors in resistance to hormone therapy. | Adv Exp Med Biol | 2007 | https://conductscience.org/library/papers/17993238 | PubMed |
| 8 | 20855825 | Results of the CONFIRM phase III trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer. | J Clin Oncol | 2010 | https://conductscience.org/library/papers/20855825 | PubMed |
| 9 | 21501600 | The turnover of estrogen receptor α by the selective estrogen receptor degrader (SERD) fulvestrant is a saturable process that is not required for antagonist efficacy. | Biochem Pharmacol | 2011 | https://conductscience.org/library/papers/21501600 | PubMed |
| 10 | 21761331 | Estrogen and progesterone in normal mammary gland development and in cancer. | Horm Cancer | 2011 | https://conductscience.org/library/papers/21761331 | PubMed |
| 11 | 22648069 | Estrogen receptors and human disease: an update. | Arch Toxicol | 2012 | https://conductscience.org/library/papers/22648069 | PubMed |
| 12 | 23178278 | Estrogen receptor-dependent and independent mechanisms of breast cancer carcinogenesis. | Steroids | 2013 | https://conductscience.org/library/papers/23178278 | PubMed |
| 13 | 23062036 | The discovery and development of selective estrogen receptor modulators (SERMs) for clinical practice. | Curr Clin Pharmacol | 2013 | https://conductscience.org/library/papers/23062036 | PubMed |
| 14 | 24373794 | Use of SERMs for treatment in postmenopausal women. | J Steroid Biochem Mol Biol | 2014 | https://conductscience.org/library/papers/24373794 | PubMed |
| 15 | 25380844 | Measuring residual estrogen receptor availability during fulvestrant therapy in patients with metastatic breast cancer. | Cancer Discov | 2015 | https://conductscience.org/library/papers/25380844 | PubMed |
| 16 | 25879485 | Identification of GDC-0810 (ARN-810), an Orally Bioavailable Selective Estrogen Receptor Degrader (SERD) that Demonstrates Robust Activity in Tamoxifen-Resistant Breast Cancer Xenografts. | J Med Chem | 2015 | https://conductscience.org/library/papers/25879485 | PubMed |
| 17 | 12040178 | Connections and regulation of the human estrogen receptor. | Science | 2002 | https://conductscience.org/library/papers/12040178 | PubMed |
| 18 | 15202583 | Hormone- and chemotherapy-induced bone loss in breast cancer. | Oncology (Williston Park) | 2004 | https://conductscience.org/library/papers/15202583 | PubMed |
| 19 | 3283939 | The steroid and thyroid hormone receptor superfamily. | Science | 1988 | https://conductscience.org/library/papers/3283939 | PubMed |
| 20 | 16421368 | Estrogen carcinogenesis in breast cancer. | N Engl J Med | 2006 | https://conductscience.org/library/papers/16421368 | PubMed |
Cited by77
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 132 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42642633 | Galanin impairs tumor immunity in glioblastoma by promoting infiltration and ferroptosis resistance of myeloid-derived suppressor cells. | Nat Cancer | 2026 | https://conductscience.org/library/papers/42642633 | PubMed |
| 42510955 | Targeting Estrogen Receptor for Breast Cancer. | Curr Issues Mol Biol | 2026 | https://conductscience.org/library/papers/42510955 | PubMed |
| 42449589 | A Real-World Study on the Effectiveness and Safety of Elacestrant in Patients with ESR1-Mutated Metastatic Breast Cancer Progressing After CDK4/6 Inhibitors and Endocrine Therapy. | Cancers (Basel) | 2026 | https://conductscience.org/library/papers/42449589 | PubMed |
| 42100504 | Deciphering inter-organ communication: The multi-organ-bone axis in osteoporosis and emerging therapeutic strategies. | J Orthop Translat | 2026 | https://conductscience.org/library/papers/42100504 | PubMed |
| 41474498 | Targeting estrogen receptor alpha in breast cancer for novel therapies resistance mechanisms and future directions. | Discov Oncol | 2025 | https://conductscience.org/library/papers/41474498 | PubMed |
| 41430072 | Biological and computer-aided evaluation of 3-methoxy-13α-estrone-16α-diphenylphosphine oxide as a new antiestrogenic agent. | Sci Rep | 2025 | https://conductscience.org/library/papers/41430072 | PubMed |
| 41383111 | The Selective Estrogen Receptor Degrader ZN-c5 Has Broad Antitumor Activity in Wild-Type and Mutant ER-Positive Breast Cancer Models. | Mol Cancer Ther | 2026 | https://conductscience.org/library/papers/41383111 | PubMed |
| 41108678 | Proteolysis-targeting chimeras in cancer therapy: Targeted protein degradation for next-generation treatment. | Cancer | 2025 | https://conductscience.org/library/papers/41108678 | PubMed |
| 40172823 | Integrating deep learning and molecular dynamics simulations for FXR antagonist discovery. | Mol Divers | 2025 | https://conductscience.org/library/papers/40172823 | PubMed |
| 40163189 | Novel Estrogen Receptor - Targeted Therapies in Hormone-Receptor Positive Breast Cancer. | Curr Treat Options Oncol | 2025 | https://conductscience.org/library/papers/40163189 | PubMed |
| 39991467 | Elacestrant in hormone receptor-positive metastatic breast cancer: a post-hoc analysis. | Explor Target Antitumor Ther | 2025 | https://conductscience.org/library/papers/39991467 | PubMed |
| 39891710 | Interaction between Estrogen Receptors and p53: A Broader Role for Tamoxifen? | Endocrinology | 2025 | https://conductscience.org/library/papers/39891710 | PubMed |
| 39821038 | Targeting Oestrogen Receptor Signalling in Breast Cancer Therapy. | Adv Exp Med Biol | 2025 | https://conductscience.org/library/papers/39821038 | PubMed |
| 39820652 | Elacestrant in Women with Estrogen Receptor-Positive and HER2-Negative Early Breast Cancer: Results from the Preoperative Window-of-Opportunity ELIPSE Trial. | Clin Cancer Res | 2025 | https://conductscience.org/library/papers/39820652 | PubMed |
| 39767607 | Current Therapeutic Opportunities for Estrogen Receptor Mutant Breast Cancer. | Biomedicines | 2024 | https://conductscience.org/library/papers/39767607 | PubMed |
| 39652577 | Imlunestrant Is an Oral, Brain-Penetrant Selective Estrogen Receptor Degrader with Potent Antitumor Activity in ESR1 Wild-Type and Mutant Breast Cancer. | Cancer Res | 2025 | https://conductscience.org/library/papers/39652577 | PubMed |
| 39585895 | Discovery of ERD-12310A as an Exceptionally Potent and Orally Efficacious PROTAC Degrader of Estrogen Receptor α (ERα). | J Med Chem | 2024 | https://conductscience.org/library/papers/39585895 | PubMed |
| 39179659 | Precision therapeutics and emerging strategies for HR-positive metastatic breast cancer. | Nat Rev Clin Oncol | 2024 | https://conductscience.org/library/papers/39179659 | PubMed |
| 39118705 | Elacestrant in the treatment landscape of ER-positive, HER2-negative, ESR1-mutated advanced breast cancer: a contemporary narrative review. | Ann Med Surg (Lond) | 2024 | https://conductscience.org/library/papers/39118705 | PubMed |
| 39022350 | Structure-Activity Relationship Study of Tris-Benzamides as Estrogen Receptor Coregulator Binding Modulators. | ACS Pharmacol Transl Sci | 2024 | https://conductscience.org/library/papers/39022350 | PubMed |
Genes3
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| ESR1 | 2099 | PubTator's text mining | https://conductscience.org/library/genes/2099 | NCBI Gene |
| ESR2 | 2100 | PubTator's text mining | https://conductscience.org/library/genes/2100 | NCBI Gene |
| INS | 3630 | PubTator's text mining | https://conductscience.org/library/genes/3630 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/26164151
GET https://conductscience.org/api/papers/v1/26164151/cited_by?page=2